Introduction to small molecule drug discovery and preclinical development
Over 90% of marketed drugs are small molecules, low molecular weight organic compounds that have been discovered, designed, and developed to prompt a specific biological process in the body. Examples include antibiotics (penicillin), analgesics (paracetamol) and synthetic hormones (corticosteroids)....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Drug Discovery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fddsv.2023.1314077/full |
| _version_ | 1797435562269868032 |
|---|---|
| author | Michelle W. Y. Southey Michael Brunavs |
| author_facet | Michelle W. Y. Southey Michael Brunavs |
| author_sort | Michelle W. Y. Southey |
| collection | DOAJ |
| description | Over 90% of marketed drugs are small molecules, low molecular weight organic compounds that have been discovered, designed, and developed to prompt a specific biological process in the body. Examples include antibiotics (penicillin), analgesics (paracetamol) and synthetic hormones (corticosteroids). On average, it takes 10–15 years to develop a new medicine from initial discovery through to regulatory approval and the total cost is often in the billions. For every drug that makes it to the market, there are many more that do not, and it is the outlay associated with abortive efforts that accounts for most of this expense. The discovery of new drugs remains a significant challenge, involving teams of researchers from chemistry, biology, drug development, computer science and informatics. In this article we will discuss the key concepts and issues encountered in small molecule preclinical drug discovery and introduce some of the emerging technologies being developed to overcome current obstacles. |
| first_indexed | 2024-03-09T10:49:30Z |
| format | Article |
| id | doaj.art-f31fa8230d5c439ca618a62ea3397293 |
| institution | Directory Open Access Journal |
| issn | 2674-0338 |
| language | English |
| last_indexed | 2024-03-09T10:49:30Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Drug Discovery |
| spelling | doaj.art-f31fa8230d5c439ca618a62ea33972932023-12-01T09:36:44ZengFrontiers Media S.A.Frontiers in Drug Discovery2674-03382023-11-01310.3389/fddsv.2023.13140771314077Introduction to small molecule drug discovery and preclinical developmentMichelle W. Y. SoutheyMichael BrunavsOver 90% of marketed drugs are small molecules, low molecular weight organic compounds that have been discovered, designed, and developed to prompt a specific biological process in the body. Examples include antibiotics (penicillin), analgesics (paracetamol) and synthetic hormones (corticosteroids). On average, it takes 10–15 years to develop a new medicine from initial discovery through to regulatory approval and the total cost is often in the billions. For every drug that makes it to the market, there are many more that do not, and it is the outlay associated with abortive efforts that accounts for most of this expense. The discovery of new drugs remains a significant challenge, involving teams of researchers from chemistry, biology, drug development, computer science and informatics. In this article we will discuss the key concepts and issues encountered in small molecule preclinical drug discovery and introduce some of the emerging technologies being developed to overcome current obstacles.https://www.frontiersin.org/articles/10.3389/fddsv.2023.1314077/fulldrug discoverysmall moleculescompound screeningartificial intelligencemultimodalities |
| spellingShingle | Michelle W. Y. Southey Michael Brunavs Introduction to small molecule drug discovery and preclinical development Frontiers in Drug Discovery drug discovery small molecules compound screening artificial intelligence multimodalities |
| title | Introduction to small molecule drug discovery and preclinical development |
| title_full | Introduction to small molecule drug discovery and preclinical development |
| title_fullStr | Introduction to small molecule drug discovery and preclinical development |
| title_full_unstemmed | Introduction to small molecule drug discovery and preclinical development |
| title_short | Introduction to small molecule drug discovery and preclinical development |
| title_sort | introduction to small molecule drug discovery and preclinical development |
| topic | drug discovery small molecules compound screening artificial intelligence multimodalities |
| url | https://www.frontiersin.org/articles/10.3389/fddsv.2023.1314077/full |
| work_keys_str_mv | AT michellewysouthey introductiontosmallmoleculedrugdiscoveryandpreclinicaldevelopment AT michaelbrunavs introductiontosmallmoleculedrugdiscoveryandpreclinicaldevelopment |